ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Pharmacosmos and Sichuan Huiyu Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

PharmacosmosSichuan Huiyu Pharmaceutical
studies on the registry5416
open to participants now59
phase 3 studies under way30
reach primary completion within a year34
programswith a study of their own in two years211

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phasePharmacosmosSichuan Huiyu Pharmaceutical
Phase 100%64%
Phase 200%

Sichuan Huiyu Pharmaceutical: 4 of its 11 programs at phase 2

  1. Test Product HY07121phase 2
  2. HY05350phase 2
  3. Test product HY0001a for injectionphase 2
  4. Test Product HYP-6589phase 2
36%
Phase 300%00%
Approved, new studies

Pharmacosmos: 2 of its 2 programs at approved, new studies

  1. iron isomaltoside 1000approved, new study
  2. trilaciclibapproved, new study
100%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Pharmacosmos2 readouts · 2 phase 3·····

Pharmacosmos, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. iron isomaltoside 1000approved, new study · Apr 30 · NCT05179226
·····

Pharmacosmos, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trilaciclibapproved, new study · Oct 31 · NCT07473128
Sichuan Huiyu Pharmaceutical2 readouts · 0 phase 3······

Sichuan Huiyu Pharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. Test Product HY07121phase 2 · May 26 · NCT06639256

Sichuan Huiyu Pharmaceutical, Jun ’27: 1 program whose next study reaches primary completion

  1. Test product HY0001a for injectionphase 2 · Jun 0 · NCT07069062
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Pharmacosmos

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Sichuan Huiyu Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionPharmacosmosSichuan Huiyu Pharmaceutical
Anemia, Iron-Deficiencyboth · compare here

Pharmacosmos in Anemia, Iron-Deficiency: 1 program

  1. iron isomaltoside 1000approved, new study

Their studies: Pharmacosmos’ studies of Anemia, Iron-Deficiency in search

Sichuan Huiyu Pharmaceutical in Anemia, Iron-Deficiency: 2 programs

  1. ferric carboxymaltosephase 1
  2. iron isomaltoside 1000phase 1

Their studies: Sichuan Huiyu Pharmaceutical’s studies of Anemia, Iron-Deficiency in search

Iron Deficienciesboth · compare here

Pharmacosmos in Iron Deficiencies: 1 program

  1. iron isomaltoside 1000approved, new study

Their studies: Pharmacosmos’ studies of Iron Deficiencies in search

Sichuan Huiyu Pharmaceutical in Iron Deficiencies: 2 programs

  1. ferric carboxymaltosephase 1
  2. iron isomaltoside 1000phase 1

Their studies: Sichuan Huiyu Pharmaceutical’s studies of Iron Deficiencies in search

Inflammatory Bowel Diseasesboth · compare here

Pharmacosmos in Inflammatory Bowel Diseases: 1 program

  1. iron isomaltoside 1000approved, new study

Their studies: Pharmacosmos’ studies of Inflammatory Bowel Diseases in search

Sichuan Huiyu Pharmaceutical in Inflammatory Bowel Diseases: 1 program

  1. iron isomaltoside 1000phase 1

Their studies: Sichuan Huiyu Pharmaceutical’s studies of Inflammatory Bowel Diseases in search

Postpartum Hemorrhageboth · compare here

Pharmacosmos in Postpartum Hemorrhage: 1 program

  1. iron isomaltoside 1000approved, new study

Their studies: Pharmacosmos’ studies of Postpartum Hemorrhage in search

Sichuan Huiyu Pharmaceutical in Postpartum Hemorrhage: 1 program

  1. iron isomaltoside 1000phase 1

Their studies: Sichuan Huiyu Pharmaceutical’s studies of Postpartum Hemorrhage in search

Renal Insufficiency, Chronicboth · compare here

Pharmacosmos in Renal Insufficiency, Chronic: 1 program

  1. iron isomaltoside 1000approved, new study

Their studies: Pharmacosmos’ studies of Renal Insufficiency, Chronic in search

Sichuan Huiyu Pharmaceutical in Renal Insufficiency, Chronic: 1 program

  1. iron isomaltoside 1000phase 1

Their studies: Sichuan Huiyu Pharmaceutical’s studies of Renal Insufficiency, Chronic in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Pharmacosmos 1 of 2 · Sichuan Huiyu Pharmaceutical 1 of 11 programs (1 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.